SCHEDULE: OrbiMed Amends Adicet Bio Stake After Offering

OrbiMed entities updated their beneficial ownership in Adicet Bio, Inc. following a registered direct offering that increased the issuer's outstanding shares.

Summary

• OrbiMed entities filed Amendment No. 8 to their Schedule 13D for Adicet Bio, Inc.
• The amendment was triggered by Adicet Bio's underwritten registered direct offering of 70,001,000 shares at $1.00 per share on October 8, 2025.
• This offering increased Adicet Bio's total outstanding shares to 153,253,530.
• OrbiMed Advisors LLC's aggregate beneficial ownership decreased to 14,772,598 shares, representing 9.6% of the class, a reduction of more than 1% due to the increased share count.
• OrbiMed Private Investments V, LP (OPI V) purchased 1,500,000 shares at $1.00 per share in the offering.
• OrbiMed Private Investments VI, LP (OPI VI) purchased 3,500,000 shares at $1.00 per share in the offering.

Sentiment

Score: 4

Explanation: While the capital raise provides funding, the significant dilution and potentially low offering price are negative for existing shareholders. OrbiMed's continued investment offers a slight positive, but the overall impact of the offering is dilutive.

Positives

• OrbiMed, a significant institutional investor, participated in the recent offering, indicating continued confidence in Adicet Bio.
• The offering raised capital for Adicet Bio, which can support its operations and strategic initiatives.

Negatives

• Existing shareholders who did not participate in the offering experienced dilution of their ownership percentage due to the issuance of 70,001,000 new shares.
• The offering price of $1.00 per share might be lower than the market price prior to the offering, potentially indicating a discount.

Future Outlook

OrbiMed entities intend to continuously review their investment in Adicet Bio based on various factors, including the company's business, financial condition, market conditions, and other opportunities. They may acquire additional shares or dispose of existing shares in the future, depending on their assessment.

Industry Context

This filing reflects a common practice in the biotechnology industry where companies raise capital through direct offerings to fund research, development, and operations. The participation of a specialized healthcare investor like OrbiMed suggests continued institutional interest in Adicet Bio's prospects, despite the dilutive nature of the offering.

Stakeholder Impact

• Shareholders: Existing shareholders experienced dilution of their ownership percentage. Shareholders who participated in the offering maintained or increased their stake.
• Company (Adicet Bio): Received significant capital ($70,001,000) to fund operations and strategic initiatives.

Next Steps

• OrbiMed entities will continue to review their investment in Adicet Bio.
• OrbiMed may acquire additional shares or dispose of existing shares in the open market or privately negotiated transactions.

Key Dates

Recommendation

The filing indicates a significant capital raise for Adicet Bio, which provides necessary funding but also results in substantial dilution for existing shareholders. While a major institutional investor like OrbiMed participated in the offering, signaling some confidence, the dilutive nature and the offering price of $1.00 per share suggest potential downward pressure or a lack of strong positive catalysts immediately following the announcement. A 'hold' recommendation allows investors to observe how the company utilizes the new capital and how the market reacts to the increased share count before making further investment decisions.

Keywords

Adicet Bio, OrbiMed, Schedule 13D, Beneficial Ownership, Registered Direct Offering, Common Stock, Biotechnology, Investment, Dilution, SEC Filing